Biography
Naveen Ramalingam, PhD, is responsible for development of microfluidics based products for both genomics and single cell applications. He has 15 years of experience in product development, systems integration, and validation at Standard BioTools. Previously he worked at National Cancer Centre Singapore on a project to develop a microfluidic nanochip for risk prediction of human hepatocellular carcinoma recurrence. Dr. Ramalingam is an active member of the American Association for Cancer Research (AACR), Associate member of Regulatory Affairs Professionals Society (RAPS), member of the American Association of Immunologists (AAI), member of the Association of Molecular Pathology (AMP) and American Association for Clinical Chemistry (AACC). He is on the editorial board member for Global Drugs and Therapeutics (GDT) journal and Annals of Nanoscience and Nanotechnology. He has written 24 peer reviewed research publications, three book chapters, and 19 conference presentations.

Talk
Revolutionizing Pharmacogenomics: qPCRpowered Simultaneous SNP, CNV, and Fragment Profiling
Traditional qPCR and CEbased methods use separate cumbersome workflows for SNP genotyping, CNV and fragment length determination. In this talk, we introduce a single workflow to simultaneously profile SNPs, CNVs, and fragment length pharmacogenomic targets using buccal swabs without extraction on a nanofluidic qPCRbased system.

Pharmacogenomics Showcase:
Standard Bio
Standard BioTools™, previously known as Fluidigm®, is driven by a bold vision – Unleashing tools to accelerate breakthroughs in human health. 

Biography
Dr Hima Challa is the Founder and Director of GenepoweRx and Pioneer in delivering Personalized Medicine. Dr Hima is Co-Investigator for Large scale Pharmacogenomics study from India.Dr Hima is member of CPIC, PGRN, ClinVar and ClinGen. Dr Hima ABIM certified Internal Medicine Physician, Academician, previously Program Director for Residency Program at Cape Fear Valley Hospital NC before venturing into startup journey with vision of delivering personalized medicine to every Individual. Dr Hima's passion in the field of Pharmacogenomics lead to start a study on 3000 individuals taking more than 4 prescription medications, measuring long term outcomes with mean followup of 2 years. Comparing the MAF of haplotypes between different ethnicities and making a comprehensive database.

Talk
Pharmacogenomic Implementation, Ethnicity Differences and Challenges
Land scape of mutations in major Pharmacogenes in Indian Population. Implementation barriers in clinical practice. Awareness of Genomics in practitioners. Our experience in translating the genomic reports into action.

Pharmacogenomics Showcase:
GenepoweRx
GenepoweRx is AI based genomic data interpretation company with key focus on bringing complex genetic data to clinical practice. Focus of the company is to empower health care professionals to deliver Personalized Medicine.

Biography
Dr. Tamaraz primary interest is identification of genetic determinants of drug response through modern methods aimed at addressing pharmacogenomics research and translating that information into new diagnostics and treatment strategies at pointofcare.

Biography
Dr. Mellios is a neuroscientist and RNA Biologist with leading expertise on circRNAs and their applications in precision medicine. He is the cofounder and CSO of Circular Genomics and an Associate Professor and University of New Mexico. He has published pivotal studies on the role of noncoding RNAs in brain function and disease and through his work at Circular Genomics has pioneered methods for the use of circRNAs for the better diagnosis and treatment of psychiatric and neurological disorders.

Pharmacogenomics Showcase:
Circular Genomics In
Circular Genomics is a pioneer in precision medicine, leveraging novel circular RNA biomarkers and bioinformatics.We are committed to delivering cutting-edge solutions that will revolutionize the way we diagnose and treat psychiatric and neurological illnesses.

Biography
Mariano Alvarez is the Chief Scientific Officer of DarwinHealth Inc, a precision-focused cancer medicine company, where he leads a team of talented researchers intended to find the best therapeutic option for every cancer patient. His interest is dissecting and pharmacologically targeting the regulatory mechanisms controlling each cell's transcriptional identity--i.e. the cell phenotypic state. At DarwinHealth, he is focused at identifying drugs able to decommission the regulatory module controlling the tumor cell state of every cancer patient, as well as drugs able to reprogram the immune-suppressive state of normal cells in the tumor microenvironment. Prior to Joining DarwinHealth, he was a PhD fellow at the University of Buenos Aires, Post-Doc trainee at Dr. Califano's Lab at Columbia University, and Research Scientist in the Department of Systems Biology at Columbia University.

Talk
Targeting the Master Regulators of Tumor and Microenvironment Cells
A small set of proteins, termed Master Regulators, form highly inter-regulated modules (Regulatory Checkpoints) that act as a molecular switch controlling the transcriptional identity (phenotypic state) of every single cell. In this presentation I will show how to systematically identify and pharmacologically target such regulatory checkpoints, leading to tumor cells demise and normal cells reprogramming.

Pharmacogenomics Showcase:
DarwinHealth
DarwinHealt is a precision-focused cancer medicine company that has developed, owns, and utilizes proprietary algorithms and methodologies to match every individual cancer patient with the drugs optimally suited to produce successful treatment outcomes.